EGFR突变型NSCLC患者在接受Lazertinib治疗期间出现的既往未被识别的独特喉部病变：病例系列

文献信息

中文摘要

Lazertinib（LECLAZA®）是第三代表皮生长因子受体酪氨酸激酶抑制剂，用于治疗非小细胞肺癌（NSCLC），尤其是伴有脑转移的患者。虽然已有皮疹和瘙痒等常见不良事件的报告，但嗓音相关并发症和结构性喉部病变此前尚未见报道。在此，我们描述了四例在接受以Lazertinib为基础的治疗期间出现新发嗓音改变或咽部异物感的NSCLC患者。喉镜检查显示多灶性、宽基底的息肉样黏膜增厚，不符合接触性肉芽肿或反流相关疾病等良性病变的典型表现。一例患者的组织病理学显示良性炎症性肉芽组织，所有病变在15-36个月的随访期间保持稳定，无进展。鉴于病例数少且存在潜在混杂因素，无法确立与Lazertinib的因果关系。然而，了解这些外观良性的黏膜表现可能有助于临床医生在评估接受Lazertinib治疗患者的咽喉或嗓音症状时，避免不必要的活检或中断癌症治疗。

英文摘要

Lazertinib (LECLAZA®) is a third-generation epidermal growth factor receptor tyrosine kinase inhibitor used to treat non-small cell lung cancer (NSCLC), especially in patients with brain metastases. While common adverse events such as rash and pruritus have been reported, voice-related complications and structural laryngeal lesions have not previously been reported. Here, we describe four NSCLC patients who developed new-onset voice changes or globus sensation during lazertinib-based therapy. Laryngoscopic examination revealed multifocal, broad-based polypoid mucosal thickening that was atypical for benign conditions such as contact granuloma or reflux-related disease. Histopathology in one patient demonstrated benign inflamed granulation tissue, and all lesions remained stable without interval progression over 15-36 months of follow-up. Given the small number of cases and the potential confounders, a causal association with lazertinib cannot be established. However, awareness of these benign-appearing mucosal findings may help clinicians avoid unnecessary biopsy or interruption of cancer treatment when evaluating throat or voice symptoms in patients receiving lazertinib therapy.